(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Xeris Biopharma Holdings's revenue in 2026 is $314,853,000.On average, 9 Wall Street analysts forecast XERS's revenue for 2026 to be $67,894,940,970, with the lowest XERS revenue forecast at $64,799,468,924, and the highest XERS revenue forecast at $70,607,147,654. On average, 9 Wall Street analysts forecast XERS's revenue for 2027 to be $83,165,130,735, with the lowest XERS revenue forecast at $76,338,863,880, and the highest XERS revenue forecast at $89,549,433,929.
In 2028, XERS is forecast to generate $95,862,953,880 in revenue, with the lowest revenue forecast at $88,351,298,067 and the highest revenue forecast at $103,507,544,075.